Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive Dendritic Cell vaccination for Lynch Syndrome (PREVENT-Lynch)
2025-524046-10-00Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancer (CRC) and Lynch syndrome-associated neoplasms, sponsored by Radboud University Medical Center. Planned start Aug 2026; status: authorised.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)colorectal cancer (CRC)Lynch syndrome-associated neoplasms
Beyond the preview
Go deeper on 2025-524046-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524046-10-00.